Sun Pharma Accounts Net profit of Rs 2,654.58 Crore in Q4

Sun Pharmaceutical Industries Ltd  revealed a united net profit of Rs 2,654.58 crore in the final quarter ended on March 31, 2024. The organization had posted a merged net benefit of Rs 1,984.47 crore in the final quarter of the past fiscal, Sun Pharmaceutical Industries said in an administrative document.

During the period under review, the total revenue from operations was Rs 11,982.9 crore. It also stated that it stood at Rs 10,930.67 crore during the same quarter a year ago. In the fourth quarter, formulation sales in India totaled Rs 3,707.8 crore, while formulation sales in the United States totaled USD 476 million, or roughly Rs 3,964 crore.

The pharmaceutical firm said the outcomes for the quarter ended on December 31, 2023, and the quarter and the year ended on March 31, 2024, are not similar with different periods because of the acquisition of 60% shareholding in Vivaldis Wellbeing and Food Pvt Ltd which was finished during the quarter ended June 30, 2023.

The board has suggested a final dividend of Rs 5 for equity share of Re 1 each dependent upon endorsement by investors at the following yearly comprehensive gathering, the organization said. It added that this is on top of the interim dividend that was paid out in FY24, which was Rs 8.5 per share. This brings the total dividend for FY24 to Rs 13.5 per share, compared to Rs 11.5 per share for FY23.